China: An Analysis Of Drug Trademark Genericide And Protection Of Brands From Dilution

Last Updated: 17 June 2014
Article by Celia Li and Xiaomeng Li

Aspirin, formerly known as a brand of painkiller manufactured by Bayer, now generally refers to any painkiller (but is still a registered trademark in Germany). It is the most typical example in the pharmaceutical industry of a registered trademark becoming a generic name. When a famous drug brand finally becomes a generic name used for similar goods even though the research and development of the drug have cost a lot and the success of the brand is due to long-term brand positioning and an accumulation of specific target consumers, it is undoubtedly a heavy blow to diligent drug researchers focusing on life saving.

I. Causes of the genericide of drug trademarks

Generic names of drugs are their legal names prepared by the Chinese Pharmacopoeia Commission in accordance with the General Principles for Nomenclature of Chinese Approved Drugs and filed with the Ministry of Health, are the generic names of drugs sharing the same ingredients or formula, and are mandatory and binding. The generic name of a drug must be used on labels, instructions or packaging of the drug to be sold on the market, while drug trademarks are distinctive signs that are used on drugs to distinguish the source. From the perspective of a trademark, the use of a drug's trade name on the drug is just the drug trademark, and shall have the distinctiveness of registered trademarks. Whether the trade name of a drug can be registered as a trademark is subject to the trademark registration procedure, without the prior permission of the health authorities; whether a drug trademark has become a generic name is subject to the judicial review for the identification in order to safeguard the rights and interests of owners of the unique names of well-known drugs. Why do trademarks originally used for specific drugs ultimately become generic names for all similar drugs? As a form of trademark dilution, the genericide of drug trademarks is mainly due to the following reasons:

1.The distinctiveness of the trademark is weak, and can be easily associated with drugs.

2.The name of the new drug is too professional, lengthy, complicated and unacceptable.

3.The acts of public authorities or external agencies, for example, the release of a drug trademark as the name of the drug by the government authorities due to negligence, and the mistaken inclusion of a trademark as a generic name into dictionaries, false publicity by the media, etc.

4.An infringer or right owner publicizes and uses a drug trademark as an alternative for the drug name for a longer time and in a wider scope.

5.When a drug brand has long been in a dominant position due to market or administrative reasons, it is also easy to result in the genericide of the trademark.

II. Danger of turning a drug trademark into a generic name

Case: In 2001, Hangzhou Minsheng Pharmaceutical Group Co., Ltd. lodged a suit stating that it had managed to register its self-developed trademark "21金维他" in 1987, and also obtained approval from the trademark office for the registration of the English trademark "21SUPER-VITA" in May 1992. In 1988, the Ministry of Health included "21金维他" in the Compilation of Standard Varieties of Chinese Drugs as a trade name. In 1990, Nanchang Sanghai Pharmaceutical Factory began to manufacture "21 金维他" on a pilot basis. On 22 May 2000, the China Food and Drug Administration issued a reply approving the change of the name of "21 金维他" as manufactured by the plaintiff to "Multivitamin and Minerals Tablets (21)" and use of "21 金维他" as a trade name, requiring use of "桑海金维" as the trade name of the "Multivitamin and Minerals Tablets (21)" manufactured by the defendant, and making it clear that the reply took effect on 1 July 2000. At present, however, the defendant still uses "21金维他" and its English version "21SUPER-VITA" for production and sales of the drug. Such use has materially violated the plaintiff's exclusive right to use the registered trademark. Nanchang Sanghai Pharmaceutical Factory argued that "21金维他" is a generic name for drugs, so its production of "21金维他" that had been included in the Compilation of Standard Varieties of Chinese Drugs upon approval complies with legislation and the provisions of the relevant regulations on drug administration. In addition, its use of the trademark "Sanghai" had been registered upon the approval of the Trademark Office. Therefore, its production and sale of "21金维他" under the Sanghai brand did not constitute trademark infringement.

This case is a typical suit triggered by the genericide of a drug trademark, which resulted in frequent conflict between the drug name and drug registered trademark. Another reason for the wide existence of such conflict is the status quo that China's drug administration is inconsistent with its trademark registration system. Health authorities believe that any approved formal drug name is the generic name of the drug. Under the Trademark Law, a generic name cannot be registered as a trademark. Therefore, any application for registration of an approved drug name as a trademark should be declined. While the Trademark Office believes that the question whether it is the generic name of the product should be based on the provisions of the Trademark Law, as long as a trademark subject to a registration application is unique with significant distinctiveness and is in line with the provisions of the Trademark Law, it should be registered regardless of whether it has been approved by the health authorities. As a result, in such a disordered management system, when a trademark becomes generic, it on one hand exists in the records of the health authorities as a generic name, and on the other hand continues to have the exclusive right with the approval of the Trademark Office. Such situation is bound to cause series of disputes, resulting in unnecessary costs and waste of resources.

As stated above, the genericide of a drug trademark can result in the co-existence of the drug name and the registered trademark. Its early consequences may be the use of the drug name by manufacturers of similar drugs. When the trademark owner seeks to safeguard its trademark right through litigation or other legal means, it is very likely that the juridical organ will identify the trademark as having turned into the drug name, and a user of such name without permission does not constitute infringement, thus encouraging other manufacturers to use the name and cause the trademark to become thoroughly generic.

When the name of a drug is also a registered trademark, does any use of the name on other drugs by anyone else without the consent of the trademark owner constitute infringement? This is undoubtedly a very important question for pharmaceutical operators and researchers. At present, there are two different views in the academic and judicial communities. One view holds that such use does not constitute trademark infringement because the existence of such conflict is a result of the inconsistent systems in China and there is no subjective fault, and the accusation of someone who uses a drug name that is also a registered trademark of constituting infringement would result in a monopoly of the drug by the manufacturer, and thus hinder economic development and social progress. The other view believes that the use constitutes infringement citing the reason that once a trademark is registered upon approval, the owner should have the exclusive right to use such trademark; therefore, the use of the same or similar trademark on the same or similar products will constitute trademark infringement if it could cause any confusion. It is groundless to defend for the reason that the trademark has become a generic name, as the generic name of a drug should be construed according to the provisions of the Trademark Law, and the rules formulated by the health authorities that regard a drug name registered by a drug manufacturer as the generic name of the drug should not conflict with the Trademark Law.

Therefore, for drug researchers and operators, due to the discrepancy between juridical theory and practice, drug manufacturers find themselves unable to predict in advance the legal consequences of their behaviour, and unable to estimate the influence on themselves once their trademarks become a generic name. This would cause more uncertainties for drug researchers and operators, or even result in unpredictable losses to drug manufacturers, for example, causing the exclusive right to use a registered trademark to exist in name, or the scope of protection for drug trademarks to be limited or to be directly revoked.

III. Protection of drug trademarks from dilution

Drug manufacturers must pay attention to the genericide of drug trademarks, and should never consider that the turning of a drug trademark into the name of certain drugs means that the drug is popular among the relevant public and can gain more popularity. In contrast, with the lapse of time, the original drug trademark will gradually enter into the public domain and have no connection with the manufacturer's trademark. In such case, the manufacturer will find it very hard to recover the value of the trademark from the drug name.

At present, there is no clear legislation on trademark dilution and dilution protection in China. When there is indication of the genericide of a drug trademark, the trademark owner has no effective weapon to curb the growth of the genericide. Therefore, it is important to take measures to prevent genericide from the beginning of use of a trademark.

1.Improve the significance of a drug trademark itself and conduct correct publicity. For example, trademarks such as "Dinggui" have been involved in litigation regarding disputes over whether they are generic names or exclusively owned trademarks because they are associated with ingredients of drugs and have lower distinctiveness, and were finally identified as generic names of drugs. The "new Contac" is widely known as a cold drug, but its packaging always contains the trademark sign®, and in advertising, the "New Contac" trademark always appears together with the generic name of the drug "Compound Pseudoephedrine Hydrochloride Sustained Release Capsules", as well as the name of the manufacturer "Tianjin Smith Kline & French Laboratories Ltd.", thus giving the relevant consumers a clear impression that "New Contac" is a drug trademark, making them always associate "New Contac" with the manufacturer.

2.Prevent the practice of directly using trademarks as generic names. "Imada Red Flower Oil" was originally used for red flower oil by the parent company of Lianhua Pharmaceutical, but has gradually become the generic name of red flower oil and has been documented by the relevant administrative authorities over a decade of use as the relevant public is accustomed to using it as the generic name for flower red oil drugs of such type. Since the words "Imada" have no connection with red flower oil drugs, Lianhua Pharmaceutical could have prevented its genericide if it had used "Imada" as a trademark prominently in its promotion efforts.

3.Pay attention to the acts of pharmaceutical health administrative authorities, and prevent relevant government agencies from adding the trademark to documents that include the compilation of drug names. Taking the trademark "Xingling" as an example, when the Pharmacopoeia Commission of the Ministry of Public Health compiled the General Principles for Nomenclature of Chinese Approved drug names for the book titled Chinese Approved Drug Names, it indicated that the name "Xingling Granule", "Xingling" is the name of the drug, while "Granule" represents the form of the drug. However, the ingredient of the drug is mainly gingko, so "Xingling" does not fully indicate the composition of the drug. Therefore, if Shanghai Xingling Pharmaceutical had prevented the health authorities from documenting the trademark as the name of the drug as early as possible, it would have been fully possible to prevent the series of disputes which occurred later.

4.Promptly take necessary legal action to stop any competitor drug manufacturer from using the trademark as name of their drug, for example, asking the Trademark Office not to register any infringing mark and ban its use, requesting the Trademark Office to withdraw any registered trademark, and meanwhile requesting the court to issue an injunction. If anyone intentionally dilutes the reputation of a well-known drug trademark, the drug manufacturer may require the person to bear the relevant damages.

Due to a lack of awareness of the protection of trademarks and incorrect use of trademarks, many pharmaceutical companies have failed to apply for the registration of their product names that have the characteristics of a trademark, or use registered trademarks as drug names, eventually leading to the wide use of these more creative names or trademarks by peers, causing them to be common resources, and finally be diluted into generic names. This causes a huge loss in the various intangible and tangible assets of the companies that are the original owners of these names. It is advised that pharmaceutical R&D enterprises avoid trademark genericide for the reason that the drug brand is too big or the method of promotion is wrong while they are researching new drugs and fostering drug brands. For this, they should pay attention to brand building, and positively take various "dilution protection" measures to increase the degree of protection of their self-made drug brands, avoid their drug trademarks being used as generic names so as to better adapt to the new trends of the pharmaceutical industry at both home and abroad, and create a good competition environment for the pharmaceutical market.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions